These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 8122301

  • 1. The chemistry of desferrioxamine chelation for aluminum overload in renal dialysis patients.
    Day JP, Ackrill P.
    Ther Drug Monit; 1993 Dec; 15(6):598-601. PubMed ID: 8122301
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Deferoxamine for aluminum toxicity in dialysis patients.
    Hernandez P, Johnson CA.
    ANNA J; 1990 Jun; 17(3):224-8. PubMed ID: 2357118
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P.
    Nephrologie; 1986 Jun; 7(5):177-80. PubMed ID: 3822038
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA, Ford DM, Gaston CE, Sedman AB, Huffer WE, Lum GM.
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [Abstract] [Full Text] [Related]

  • 9. [The causes of aluminum cumulation and poisoning in patients with chronic kidney failure treated by hemodialysis on a regular program and the possibilities for therapy].
    Válek A, Sulková S, Laurinová Z.
    Ter Arkh; 1991 Oct; 63(6):89-93. PubMed ID: 1948757
    [No Abstract] [Full Text] [Related]

  • 10. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST, Pedersen FB.
    Nephrol Dial Transplant; 1989 Oct; 4(7):676. PubMed ID: 2510071
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
    Yokel RA.
    J Toxicol Environ Health; 1994 Feb; 41(2):131-74. PubMed ID: 8301696
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ, Walker JV, Boykin JL.
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P, Gmeiner R, Beck G, König P.
    Wien Med Wochenschr; 1987 Aug 15; 137(14-15):355-60. PubMed ID: 3673100
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Speech apraxia in dialysis-associated aluminum encephalopathy].
    Haug BA, Botsch G, Felgenhauer K.
    Nervenarzt; 1991 Oct 15; 62(10):637-40. PubMed ID: 1749454
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.